Annual EBITDA
-$58.03 M
+$49.63 M+46.10%
December 31, 2023
Summary
- As of February 7, 2025, STRO annual EBITDA is -$58.03 million, with the most recent change of +$49.63 million (+46.10%) on December 31, 2023.
- During the last 3 years, STRO annual EBITDA has fallen by -$34.28 million (-144.32%).
- STRO annual EBITDA is now -888.09% below its all-time high of $7.36 million, reached on December 31, 2016.
Performance
STRO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$39.08 M
-$1.90 M-5.12%
September 30, 2024
Summary
- As of February 7, 2025, STRO quarterly EBITDA is -$39.08 million, with the most recent change of -$1.90 million (-5.12%) on September 30, 2024.
- Over the past year, STRO quarterly EBITDA has dropped by -$96.41 million (-168.16%).
- STRO quarterly EBITDA is now -168.16% below its all-time high of $57.34 million, reached on December 31, 2023.
Performance
STRO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$65.97 M
-$2.05 M-3.20%
September 30, 2024
Summary
- As of February 7, 2025, STRO TTM EBITDA is -$65.97 million, with the most recent change of -$2.05 million (-3.20%) on September 30, 2024.
- Over the past year, STRO TTM EBITDA has dropped by -$7.94 million (-13.68%).
- STRO TTM EBITDA is now -373.59% below its all-time high of $24.11 million, reached on September 30, 2020.
Performance
STRO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
STRO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.1% | -168.2% | -13.7% |
| 3 y3 years | -144.3% | -168.2% | -13.7% |
| 5 y5 years | -77.6% | -168.2% | -13.7% |
STRO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.1% | -168.2% | +16.9% | -13.7% | +55.8% |
| 5 y | 5-year | -144.3% | +46.1% | -168.2% | +35.5% | -373.6% | +55.8% |
| alltime | all time | -888.1% | +46.1% | -168.2% | +35.5% | -373.6% | +55.8% |
Sutro Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$39.08 M(+5.1%) | -$65.97 M(+3.2%) |
| Jun 2024 | - | -$37.18 M(-21.0%) | -$63.93 M(+6.5%) |
| Mar 2024 | - | -$47.05 M(-182.1%) | -$60.04 M(+3.4%) |
| Dec 2023 | -$58.03 M(-46.1%) | $57.34 M(-254.8%) | -$58.03 M(-61.1%) |
| Sep 2023 | - | -$37.03 M(+11.3%) | -$149.13 M(+17.1%) |
| Jun 2023 | - | -$33.28 M(-26.1%) | -$127.36 M(+10.2%) |
| Mar 2023 | - | -$45.05 M(+33.5%) | -$115.60 M(+7.4%) |
| Dec 2022 | -$107.67 M(+10.4%) | -$33.76 M(+121.2%) | -$107.67 M(-2.2%) |
| Sep 2022 | - | -$15.26 M(-29.1%) | -$110.11 M(-11.1%) |
| Jun 2022 | - | -$21.52 M(-42.0%) | -$123.81 M(+16.3%) |
| Mar 2022 | - | -$37.13 M(+2.6%) | -$106.47 M(+9.1%) |
| Dec 2021 | -$97.56 M(+310.7%) | -$36.20 M(+25.0%) | -$97.56 M(-20.0%) |
| Sep 2021 | - | -$28.96 M(+592.1%) | -$121.98 M(+68.0%) |
| Jun 2021 | - | -$4.18 M(-85.2%) | -$72.59 M(+110.3%) |
| Mar 2021 | - | -$28.21 M(-53.5%) | -$34.52 M(+45.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$23.75 M(-49.0%) | -$60.62 M(-396.8%) | -$23.75 M(-198.5%) |
| Sep 2020 | - | $20.42 M(-39.7%) | $24.11 M(-452.1%) |
| Jun 2020 | - | $33.89 M(-294.3%) | -$6.85 M(-86.9%) |
| Mar 2020 | - | -$17.44 M(+36.7%) | -$52.10 M(+11.8%) |
| Dec 2019 | -$46.62 M(+42.6%) | -$12.76 M(+21.0%) | -$46.62 M(+27.8%) |
| Sep 2019 | - | -$10.54 M(-7.3%) | -$36.48 M(+5.5%) |
| Jun 2019 | - | -$11.37 M(-4.9%) | -$34.58 M(+1.2%) |
| Mar 2019 | - | -$11.95 M(+355.7%) | -$34.18 M(+4.4%) |
| Dec 2018 | -$32.68 M(+133.3%) | -$2.62 M(-69.6%) | -$32.72 M(-25.3%) |
| Sep 2018 | - | -$8.63 M(-21.2%) | -$43.80 M(+24.6%) |
| Jun 2018 | - | -$10.96 M(+4.4%) | -$35.15 M(+45.3%) |
| Mar 2018 | - | -$10.50 M(-23.3%) | -$24.18 M(+76.7%) |
| Dec 2017 | -$14.01 M(-290.2%) | -$13.70 M(<-9900.0%) | -$13.68 M(<-9900.0%) |
| Sep 2017 | - | $13.00 K | $13.00 K |
| Dec 2016 | $7.36 M | - | - |
FAQ
- What is Sutro Biopharma annual EBITDA?
- What is the all time high annual EBITDA for Sutro Biopharma?
- What is Sutro Biopharma annual EBITDA year-on-year change?
- What is Sutro Biopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sutro Biopharma?
- What is Sutro Biopharma quarterly EBITDA year-on-year change?
- What is Sutro Biopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Sutro Biopharma?
- What is Sutro Biopharma TTM EBITDA year-on-year change?
What is Sutro Biopharma annual EBITDA?
The current annual EBITDA of STRO is -$58.03 M
What is the all time high annual EBITDA for Sutro Biopharma?
Sutro Biopharma all-time high annual EBITDA is $7.36 M
What is Sutro Biopharma annual EBITDA year-on-year change?
Over the past year, STRO annual EBITDA has changed by +$49.63 M (+46.10%)
What is Sutro Biopharma quarterly EBITDA?
The current quarterly EBITDA of STRO is -$39.08 M
What is the all time high quarterly EBITDA for Sutro Biopharma?
Sutro Biopharma all-time high quarterly EBITDA is $57.34 M
What is Sutro Biopharma quarterly EBITDA year-on-year change?
Over the past year, STRO quarterly EBITDA has changed by -$96.41 M (-168.16%)
What is Sutro Biopharma TTM EBITDA?
The current TTM EBITDA of STRO is -$65.97 M
What is the all time high TTM EBITDA for Sutro Biopharma?
Sutro Biopharma all-time high TTM EBITDA is $24.11 M
What is Sutro Biopharma TTM EBITDA year-on-year change?
Over the past year, STRO TTM EBITDA has changed by -$7.94 M (-13.68%)